

Heatmap across headline COPD targets

- Recent IL-33 flops jolts COPD strategy - momentum now sits with Type-2 winners (Dupixent approved, Nucala revived, TSLP in Phase-3) and fresh small molecule gains like inhaled PDE3/4

● Approved
● Ph 2/3
● Ph1 or PC

	AMGEN	AstraZeneca	Bristol Myers Squibb	GSK	HENGROI	J&J	MERCK	Pfizer	REGENERON	Roche	sonofi	Leading Biotech (in COPD)
IL-33 / IL-33R / ST2	● Astegolimab	● Tozorakimab	✗	● GSK3862995B	✗	✗	✗	Not in COPD PF-07264660	● Itepekimab	● Astegolimab	● Itepekimab	● 9MW1911 (Mabwell)
TSLP	● Tezepelumab	Not in COPD AZD8630	Not in COPD Bempikibart	● SHR-1905	● SHR-1905	✗	● Solrikutug	Not in COPD PF-07275315	✗	✗	Not in COPD Lunsekimig	● Bosakitug (Aclaris Tx)
IL-4/13 or IL-4Rα	✗	✗	✗	✗	✗	✗	✗	Not in COPD PF-0726 / 0727	● Dupilumab	✗	● Dupilumab	● Rademikibart (Connect Bio)
IL-5 / IL-5R	✗	● Benralizumab	✗	● Mepolizumab	Not in COPD SHR-1703	✗	Not in COPD Reslizumab	✗	✗	✗	✗	● RC1416 (Regenecore)
IL-17/23	✗	✗	✗	✗	✗	✗	✗	✗	✗	✗	✗	● OKRA-021 (Oruka Tx)
PDE3/4	Not in COPD Apremilast	● Roflumilast	✗	✗	● HRS-9821	✗	● Ensifentrine	Not in COPD Crisaborole	✗	✗	● Multiple	✗
NLRP3	✗	Not in COPD AZD4144	✗	✗	✗	Not in COPD Patent-mined	Not in COPD Patent-mined	✗	✗	● Somalix	Not in COPD Patent-mined	● (NeuShen Tx)

Lead asset displayed; active development only; stage of development is highest globally within COPD – assets for that target are shown if not pursuing COPD, but labeled with a red box

Trending negatively
Trending positively